#Italy #Milan #Sinocare #Diabetes Care #EASD 2026

Sinocare Showcases Integrated Chronic Disease Management Solutions at EASD 2026

Sinocare, a leading innovator in diabetes care, recently showcased its integrated chronic disease management solutions at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), held in Milan from September 28 to October 2, 2026. This year's conference allowed Sinocare to present a comprehensive portfolio specifically crafted to address the different stages of chronic disease management, from initial risk assessments to daily monitoring and clinical testing.

Home Care Innovations

For individuals managing diabetes at home, Sinocare introduced the Safe AQ max II Blood Glucose Monitoring System. This device stands out for its rapid five-second blood glucose results, Bluetooth data synchronization, and the ability to tag results pre- and post-meals. Sinocare also unveiled the KUG-11 Glucose, Uric Acid and Ketone Meter, which effectively combines three metabolic tests into one device. Additionally, pet owners can benefit from the GV-100 Veterinary Blood Glucose Monitoring System, designed to assist in at-home diabetes care for both dogs and cats.

Enhancements for Community Pharmacies

Transitioning to community pharmacy solutions, Sinocare showcased the iCARE-1300 Portable Automatic Multifunction Analyzer, which offers automated testing for nearly 100 health parameters, including blood glucose levels, lipid profiles, HbA1c, and renal function. This device provides results in just 3 to 15 minutes, allowing pharmacists to improve chronic disease screening and risk assessments. Furthermore, through its Health Station model, Sinocare is expanding pharmacy capabilities in chronic disease management.

Hospital Solutions

In hospital settings, Sinocare presents the AGEscan Advanced Glycation End Products Fluorescence Detector, a revolutionary device that facilitates non-invasive detection of AGEs without blood sampling. This technology aids in early risk screening, making hospital environments more efficient in managing chronic disease care. Additionally, the Safe AQ 8000 Hospital Blood Glucose Smart Management System is designed to seamlessly integrate with hospital Health Information Systems (HIS), capturing glucose meter and continuous glucose monitoring (CGM) data through a Doctor Web Portal. This system is pivotal for bedside testing and ongoing patient monitoring.

Sinocare’s Vision

Sinocare's comprehensive approach demonstrates its commitment to seamlessly connect various stages of screening, monitoring, and long-term management within multiple care settings. As the company continues to innovate in biosensing technologies, it aims to enhance the accessibility and connectivity of chronic disease management solutions on a global scale.

Established in 2002, Sinocare is China's pioneer in blood glucose monitoring devices and the nation's largest manufacturer, holding over 780 patents across nine R&D and production sites worldwide. With a mission to integrate biosensing, AI, and healthcare, Sinocare serves more than 25 million users in 187 countries, positioning itself among the world's top four blood glucose meter companies. Their focus on chronic disease solutions speaks volumes about their dedication to improving healthcare outcomes worldwide.

For more detailed insights into Sinocare's offerings and its latest innovations, visit www.sinocare.com/en.